Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in T1 urothelial urinary bladder carcinoma?

Urologia Internationalis

Volumn 80, Issue 4, 2008, Pages 413-418

  Soukup, V ^a,b   Babjuk, M ^a   Duskova J ^a   Pesl M ^a   Szakaczova M ^a   Zamecnik L ^a   Dvoracek J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Fascin 1; T1 subclassification; Urothelial carcinoma of the urinary bladder

Indexed keywords

ACTIN BINDING PROTEIN; FASCIN 1; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER MUSCLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL RATE; TRANSURETHRAL RESECTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CARRIER PROTEINS; CONFIDENCE INTERVALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 46249085706     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000132700     Document Type: Article

References (25)

1. Fleming ID, Cooper IS, Henson DE, Hutter RVP, et al: American Joint Committee on Cancer, Cancer Staging Manual. Philadelphia, Raven &Lippincott, 1997.
2. Heney NM, Ahmed S, Flanagan MJ, et al; National Bladder Cancer Collaborative Group: Superficial bladder cancer progression and recurrence. J Urol 1983;130:1083-1086.
3. Kiemeney LALM, Witjes JA, Heibroek RP, et al: Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;150:60-64.
4. Catalona WJ, Dresner SM, Haaff EO: Management of superficial bladder cancer;in Skinner DG, and Lieskovsky G (eds): Diagnosis and Management of Genitourinary Cancer. New York, Alan R Liss, 1988, pp 284-294.
5. Ioachim F, Michael M, Salmas M, Michael MM, Stavropoulos NE, Malamou-Mitsi V: Hypoxia-inducible factors HIF-1 and HIF-2 expression in bladder cancer and their association with other angiogenesis-related proteins. Urol Int 2006;77:255-263.
6. Smits G, Schaafsma E, Kiemeney L, et al: Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risk of progression. Urology 1998;52:1009-1014.
7. Holmäng S, Hedelin H, Anderström C, et al: The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997;157:800-804.
8. Orsola A, Trias I, Raventos CX, Espanol I, Cecchini L, Búcar S, et al: Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005;48:231-238.
9. Dixon JS, Gosling JA: Histology and fine structure of the muscularis mucosae of human urinary bladder. J Anat 1983;136:265-269.
10. Keep JC, Piehl M, Miller A, et al: Invasive carcinomas of the urinary bladder. Evaluation of tunica muscularis mucosal involvement. Am J Clin Pathol 1989;91:575-579.
11. Younes M, Sussman J, True LD, et al: The usefulness of the level of the muscularis mucosae in staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990;66:543-547.
12. Hasuy Y, Osada Y, Kitada S, et al: Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology 1994;43:782-786.
13. Yamashiro S, Matsumura F: Intracellular localization of the 55-kD actin-binding protein in cultured cells: spatial relationships with actin, alpha-actin, tropomyosin and fimbrin. J Cell Biol 1986;103:631-640.
14. Edwards RA, Bryan J: Fascins, a family of actin bundling proteins. Cell Motil Cytoskeleton 1995;32:1-9.
15. Saishin Y, Shimada S, Morimura H, et al: Isolation of a cDNA encoding a photoreceptor cell-specific actin-bundling protein: retinal fascin. FEBS Lett 1997;414:381-386.
16. Tubb BE, Bardien-Kruger S, Kashork CD, et al: Characterisation of human retinal fascin gene (FSCN2) at 17q25: close physical linkage of fascin and cytoplasmic actin genes. Genomic 2000;65:146-156.
17. Duh FM, Latif F, Weng Y, et al: cDNA cloning and expression of the human homolog of the sea urchin fascin and Drosophila signed genes which encodes actin-bundling protein. DNA Cell Biol 1994;13:821-827.
18. Pelosi G, Pastorino U, Pasini F, et al: Independent prognostic value of fascin immunoreactivity in stage I non-small cell lung cancer 2003;88:537-547.
19. Grothey A, Hashizume R, Sahin AA, et al: Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 2000;83:870-873.
20. Maitra A, Adsay NV, Argani P, et al: Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003;16:902-912.
21. Jawhari AU, Buda A, Jenkins M, et al: Fascin, an actin bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 2003;162:69-80.
22. Hu W, McCrea PD, Deavers M, et al: Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian tumors. Clin Exp Metastasis 2000;18:83-88.
23. Goncharuk VN, Ross JS, Carlson JA, et al: Actin-binding protein fascin expression in skin neoplasia. J Cutan Pathol 2002;29:430-438.
24. Tong GX, Yee H, Chiriboga L, et al: Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Human Pathol 2005;36:741-746.
25. Platz CE, Cohen MB, Jones MP, et al: Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol 1996;9:1035-1039.